The specifics, since they change the answer: 15 mg · three weeks · vomiting.
I would like the mechanism, because I want to be able to reason about the cases nobody has written about.
I have tried to reason it out from first principles and got to two contradictory conclusions.
Can someone derive this rather than assert it?
three weeks at 15 mg is 21 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 15 mg back by 21 days. Whether that reduces vomiting depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 15 mg is 15 mg on day 1 and on day 21. A symptom driven by the rate of change has 21 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot vomiting against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Four half-lives between steps, minimum. Work it out for your agent.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Slower costs time and nothing else. The ceiling is the same.
The relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
To be exact about it, escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
The top of the schedule is not the target. The working dose is.
More usefully, this is the single most consequential controllable variable in the whole experience, and people routinely rush it.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Stepping back is a normal adjustment, not a failure.
The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.
Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
The caveat that matters: dose decisions on a licensed medicine belong with a prescriber, and dose decisions on research-use-only material belong to a category where nobody has any obligation to you at all.
Hold rather than escalate while symptoms are active. Always.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.